Neteera Technologies vs Moderna

Side-by-side comparison of AI visibility scores, market position, and capabilities

Moderna leads in AI visibility (90 vs 36)
Neteera Technologies logo

Neteera Technologies

EmergingHealthcare

Contactless Remote Patient Monitoring

Israeli healthtech with FDA-cleared and CE-certified contactless RPM system that captures vital signs without sensors touching the patient; $6.7M Series B; 11–50 employees; active clinical deployments.

AI VisibilityBeta
Overall Score
D36
Category Rank
#529 of 596
AI Consensus
74%
Trend
stable
Per Platform
ChatGPT
31
Perplexity
39
Gemini
30

About

Neteera Technologies is an Israeli digital health company developing contactless remote patient monitoring (RPM) solutions that capture vital signs and behavioral parameters without any physical contact with the patient. Founded and headquartered in Israel, Neteera's technology uses proprietary radar-based sensing to measure respiration rate, heart rate, body movement, and other physiological signals through a bedside device — no wearables, electrodes, or patient cooperation required. This contactless approach is particularly valuable for patients who cannot tolerate wearable sensors (elderly, agitated, or critically ill patients) and for settings requiring continuous monitoring without nursing staff intervention.

Full profile
Moderna logo

Moderna

LeaderHealthcare Tech

Enterprise

mRNA pioneer with $3.2B FY2024 revenue (down from $18.4B 2022 COVID peak); mRESVIA RSV vaccine approved 2024; personalized cancer vaccine with Merck shows 44% recurrence reduction in melanoma.

AI VisibilityBeta
Overall Score
A90
Category Rank
#2 of 596
AI Consensus
83%
Trend
stable
Per Platform
ChatGPT
92
Perplexity
93
Gemini
89

About

Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stéphane Bancel, and others in Cambridge, Massachusetts, where it is headquartered and trades on Nasdaq (MRNA). The company achieved extraordinary commercial success with Spikevax, its COVID-19 mRNA vaccine developed in partnership with the U.S. government in 2020—generating $18.4 billion in COVID vaccine revenues in 2022 at peak—before experiencing a severe revenue decline as global COVID booster demand normalized. For FY2024, Moderna generated approximately $3.2 billion in revenues, with Spikevax and the reformulated XBB.1.5-targeting COVID vaccine contributing the majority, while the company's significant R&D investment pipeline consumed most operating cash flows.

Full profile

AI Visibility Head-to-Head

36
Overall Score
90
#529
Category Rank
#2
74
AI Consensus
83
stable
Trend
stable
31
ChatGPT
92
39
Perplexity
93
30
Gemini
89
38
Claude
96
31
Grok
95

Key Details

Category
Contactless Remote Patient Monitoring
Enterprise
Tier
Emerging
Leader
Entity Type
brand
company

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.